After five major court decisions on the 340B contract pharmacy standoff and no quick resolution in sight, expect Congress to end the fight over contract pharmacy before the 2022 midterm elections, 340B Report Publisher and CEO Ted Slafsky predicts in
…
Makers of seven of 10 top drugs in the U.S. hiked those drugs’ prices substantially in 2020 with no new evidence of improved safety or effectiveness, led by AbbVie’s anti-inflammatory blockbuster Humira, an influential drug pricing watchdog group says.
The American Hospital Association (AHA) has pushed back on a JAMA Internal Medicine study suggesting that leading acute care facilities that are 340B covered entities have wide variations in how much they charge insurers for clinician-administered drugs.
Although Congress was able to pass a $1.2 trillion bipartisan infrastructure package last week, the nearly $1.8 trillion Build Back Better bill remains bogged down by infighting among Democrats.
Democratic lawmakers have come to an agreement for placing a limited drug price negotiation plan for the Medicare program into the Build Back Better bill, but how it will impact the 340B program remains to be seen.
Sectyr, an established provider of compliance platforms for 340B covered entities, has acquired LicenseTrak, a system for managing license, contract, training, and other business tasks, the companies announced last week.
California’s Medicaid (Medi-Cal) program remains on track to move its pharmacy benefit from managed care to fee-for-service early next year, a change that would deprive federally qualified health centers and other safety net health care providers of hundreds of millions
…
If Congress changes hands during next year’s mid-term elections, we can expect the 340B program to be back under the spotlight with a renewed effort to place significant restrictions on the program, 340B Report Publisher and CEO Ted Slafsky writes
…
The ban on 340B discounts on orphan drugs for rural and free-standing cancer hospitals may give drug companies a powerful incentive “to seek orphan designation for drugs approved to treat common diseases or conditions,” the U.S. Health and Human Services
…
Hundreds of family planning clinics that lost their Title X federal grants and 340B eligibility because they opposed a Trump-era rule barring them from providing abortion referrals might return to Title X and 340B soon.
